- Home
- EKSO vs BIAF Comparison
EKSO vs BIAF Comparison
Compare EKSO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- BIAF
- Stock Information
- Founded
- EKSO 2005
- BIAF 2014
- Country
- EKSO United States
- BIAF United States
- Employees
- EKSO N/A
- BIAF N/A
- Industry
- EKSO Medical/Dental Instruments
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EKSO Health Care
- BIAF Health Care
- Exchange
- EKSO Nasdaq
- BIAF Nasdaq
- Market Cap
- EKSO 11.6M
- BIAF 12.2M
- IPO Year
- EKSO N/A
- BIAF 2022
- Fundamental
- Price
- EKSO $0.42
- BIAF $0.21
- Analyst Decision
- EKSO Strong Buy
- BIAF Hold
- Analyst Count
- EKSO 2
- BIAF 1
- Target Price
- EKSO $2.50
- BIAF N/A
- AVG Volume (30 Days)
- EKSO 134.7K
- BIAF 670.4K
- Earning Date
- EKSO 05-05-2025
- BIAF 05-14-2025
- Dividend Yield
- EKSO N/A
- BIAF N/A
- EPS Growth
- EKSO N/A
- BIAF N/A
- EPS
- EKSO N/A
- BIAF N/A
- Revenue
- EKSO $17,544,000.00
- BIAF $9,362,022.00
- Revenue This Year
- EKSO $25.17
- BIAF N/A
- Revenue Next Year
- EKSO $37.02
- BIAF $19.99
- P/E Ratio
- EKSO N/A
- BIAF N/A
- Revenue Growth
- EKSO N/A
- BIAF 269.68
- 52 Week Low
- EKSO $0.34
- BIAF $0.16
- 52 Week High
- EKSO $1.53
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- EKSO 46.18
- BIAF 29.98
- Support Level
- EKSO $0.38
- BIAF $0.16
- Resistance Level
- EKSO $0.43
- BIAF $0.48
- Average True Range (ATR)
- EKSO 0.04
- BIAF 0.05
- MACD
- EKSO -0.00
- BIAF -0.03
- Stochastic Oscillator
- EKSO 33.11
- BIAF 8.68
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.